Celldex To Fly Solo With Phase III Trial Of Brain Cancer Vaccine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
All on its own, Celldex is gearing up to run a Phase III trial in the second half of 2011, testing its therapeutic cancer vaccine rindopepimut in newly diagnosed glioblastoma, after releasing positive results from ACT III, the last of three trials in its Phase II program.
You may also be interested in...
Faster FDA Review A Possibility For Celldex’s Rintega After Phase II
Celldex presented positive data from a Phase II study testing the therapeutic cancer vaccine Rintega in patients with EGFRvIII-positive recurrent glioblastoma, including a survival advantage, at ASCO.
Celldex Differentiated Immuno-Oncology Asset Ripe For Combos
Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.
Celldex Differentiated Immuno-Oncology Asset Ripe For Combos
Celldex Therapeutics will initiate Phase I/II trials of its immunotherapy varlilumab in combination with Bristol’s PD-1 inhibitor nivolumab this year and is exploring multiple other combinations.